|
|
Prepublished online as a Blood First Edition Paper on May 17, 2002; DOI 10.1182/blood-2002-01-0048.
 Previous Article | Table of Contents | Next Article 
Blood, 1 September 2002, Vol. 100, No. 5, pp. 1525-1531
PLENARY PAPER
A randomized multicenter comparison of bone marrow and peripheral
blood in recipients of matched sibling allogeneic transplants for
myeloid malignancies
Stephen Couban,
David R. Simpson,
Michael J. Barnett,
Christopher Bredeson,
Lothar Hubesch,
Kang Howson-Jan,
Tsiporah B. Shore,
Irwin R. Walker,
Peter Browett,
Hans A. Messner,
Tony Panzarella, and
Jeffrey H. Lipton for
the Canadian Bone Marrow Transplant Group
From the Department of Medicine, Dalhousie University
and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada;
North Shore Hospital, Takapuna, Auckland, New Zealand; Vancouver
Hospital and Health Sciences Centre and British Columbia Cancer Agency,
Vancouver, BC, Canada; Statistical Center of the International Bone
Marrow Transplant Registry, Health Policy Institute, Medical College of
Wisconsin, Milwaukee; Department of Medicine, Ottawa Hospital and
University of Ottawa, ON, Canada; Departments of Medicine and Oncology,
London Health Sciences Centre and London Regional Cancer Centre,
University of Western Ontario, London, ON, Canada; Weill Medical
College of Cornell University, New York Presbyterian Hospital, New
York; Department of Medicine, McMaster University, Hamilton, ON,
Canada; Division of Molecular Medicine, Faculty of Medical and Health
Sciences, University of Auckland, New Zealand; and Departments of
Medical Oncology and Biostatistics, Princess Margaret Hospital and
University of Toronto, ON, Canada.
Cytokine-mobilized peripheral blood is increasingly used instead of
bone marrow as the source of cells for allogeneic transplantation. Although cells lead to faster hematologic recovery, their effects on
graft-versus-host disease, relapse, and survival are less certain. Between January 1996 and February 2000, 228 patients with chronic myeloid leukemia, acute myeloid leukemia, or myelodysplasia were randomized to receive either bone marrow or peripheral blood allografts from HLA-matched siblings. All patients received busulfan and cyclophosphamide as conditioning chemotherapy and cyclosporine and
methotrexate as graft-versus-host disease prophylaxis. We compared the
times to neutrophil and platelet recovery, acute and chronic
graft-versus-host disease, relapse, and overall survival between the
groups. The median times to neutrophil recovery were 19 days and 23 days and the times to platelet recovery were 16 days and 22 days in the
peripheral blood and bone marrow groups, respectively
(P < .0001 for both comparisons). The cumulative incidence of grades II to IV acute graft-versus-host disease 100 days
after transplantation was 44% in both groups (hazard ratio, 0.99; 95%
confidence interval, 0.66-1.49; P > .9), and the
incidence of extensive chronic graft-versus-host disease at 30 months
after transplantation was 40% with peripheral blood and 30%
with bone marrow (hazard ratio, 1.23; 95% confidence interval,
0.78-1.96; P = .37). There was no statistically
significant difference in the probability of relapse of the underlying
disease between the groups. The probabilities of survival at 30 months
after transplantation were 68% and 60% in the peripheral
blood and bone marrow groups, respectively (hazard ratio, 0.62; 95%
confidence interval, 0.39-0.97; P = .04). In patients
with chronic myeloid leukemia, acute myeloid leukemia, and
myelodysplasia undergoing allogeneic transplantation from matched
siblings, the use of peripheral blood instead of bone marrow leads to
faster hematologic recovery, similar risk of graft-versus-host disease,
and improved survival.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. L. Irani, C. S. Cutler, E. E. Whang, T. E. Clancy, S. Russell, R. S. Swanson, S. W. Ashley, M. J. Zinner, and C. P. Raut
Severe Acute Gastrointestinal Graft-vs-Host Disease: An Emerging Surgical Dilemma in Contemporary Cancer Care
Arch Surg,
November 1, 2008;
143(11):
1041 - 1045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Gahrton, S. Iacobelli, G. Bandini, B. Bjorkstrand, P. Corradini, C. Crawley, U. Hegenbart, G. Morgan, N. Kroger, A. Schattenberg, et al.
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma
Haematologica,
November 1, 2007;
92(11):
1513 - 1518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Schmitz, M. Eapen, M. M. Horowitz, M.-J. Zhang, J. P. Klein, J. D. Rizzo, F. R. Loberiza, A. Gratwohl, and R. E. Champlin
Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation
Blood,
December 15, 2006;
108(13):
4288 - 4290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Pastos, W. B. Slayton, L. M. Rimsza, L. Young, and M. C. Sola-Visner
Differential effects of recombinant thrombopoietin and bone marrow stromal-conditioned media on neonatal versus adult megakaryocytes
Blood,
November 15, 2006;
108(10):
3360 - 3362.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Crawley, R. Szydlo, M. Lalancette, A. Bacigalupo, A. Lange, M. Brune, G. Juliusson, A. Nagler, A. Gratwohl, J. Passweg, et al.
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT
Blood,
November 1, 2005;
106(9):
2969 - 2976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. B. Slayton, D. A. Wainman, X. M. Li, Z. Hu, A. Jotwani, C. R. Cogle, D. Walker, R. C. Fisher, J. R. Wingard, E. W. Scott, et al.
Developmental Differences in Megakaryocyte Maturation Are Determined by the Microenvironment
Stem Cells,
September 1, 2005;
23(9):
1400 - 1408.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Z. Pavletic, I. F. Khouri, M. Haagenson, R. J. King, P. J. Bierman, M. R. Bishop, M. Carston, S. Giralt, A. Molina, E. A. Copelan, et al.
Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research
J. Clin. Oncol.,
August 20, 2005;
23(24):
5788 - 5794.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Stem Cell Trialists' Collaborative Group
Allogeneic Peripheral Blood Stem-Cell Compared With Bone Marrow Transplantation in the Management of Hematologic Malignancies: An Individual Patient Data Meta-Analysis of Nine Randomized Trials
J. Clin. Oncol.,
August 1, 2005;
23(22):
5074 - 5087.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Lipkin, P. Lenssen, and B. J. Dickson
Nutrition Issues in Hematopoietic Stem Cell Transplantation: State of the Art
Nutr Clin Pract,
August 1, 2005;
20(4):
423 - 439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Wallen, T. A. Gooley, H. J. Deeg, J. M. Pagel, O. W. Press, F. R. Appelbaum, R. Storb, and A. K. Gopal
Ablative Allogeneic Hematopoietic Cell Transplantation in Adults 60 Years of Age and Older
J. Clin. Oncol.,
May 20, 2005;
23(15):
3439 - 3446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Cao, J. A. Shizuru, R. M. Wong, K. Sheehan, G. G. Laport, K. E. Stockerl-Goldstein, L. J. Johnston, M. J. Stuart, F. C. Grumet, R. S. Negrin, et al.
Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose
Blood,
March 15, 2005;
105(6):
2300 - 2306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Wall
Allogeneic Peripheral Blood Versus Bone Marrow Transplantation: Children Are Small Adults and More
J. Clin. Oncol.,
December 15, 2004;
22(24):
4865 - 4866.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Eapen, M. M. Horowitz, J. P. Klein, R. E. Champlin, F. R. Loberiza Jr, O. Ringden, and J. E. Wagner
Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry
J. Clin. Oncol.,
December 15, 2004;
22(24):
4872 - 4880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Diaconescu, C. R. Flowers, B. Storer, M. L. Sorror, M. B. Maris, D. G. Maloney, B. M. Sandmaier, and R. Storb
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
Blood,
September 1, 2004;
104(5):
1550 - 1558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Leger and T. J. Nevill
Hematopoietic stem cell transplantation: a primer for the primary care physician
Can. Med. Assoc. J.,
May 11, 2004;
170(10):
1569 - 1577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.C. Taussig, A.J. Davies, J.D. Cavenagh, H. Oakervee, D. Syndercombe-Court, S. Kelsey, J.A.L. Amess, A.Z.S. Rohatiner, T.A. Lister, and M.J. Barnett
Durable Remissions of Myelodysplastic Syndrome and Acute Myeloid Leukemia After Reduced-Intensity Allografting
J. Clin. Oncol.,
August 15, 2003;
21(16):
3060 - 3065.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Cottler-Fox, T. Lapidot, I. Petit, O. Kollet, J. F. DiPersio, D. Link, and S. Devine
Stem Cell Mobilization
Hematology,
January 1, 2003;
2003(1):
419 - 437.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Maloney, B. M. Sandmaier, S. Mackinnon, and J. A. Shizuru
Non-Myeloablative Transplantation
Hematology,
January 1, 2002;
2002(1):
392 - 421.
[Abstract]
[Full Text]
|
|
|
|
|
